Adenocarcinoma at the gastroesophageal junction

Annals of the New York Academy of Sciences

Volumn 1325, Issue 1, 2014, Pages 211-225

  Al Haddad, Sahar ^a   Chang, Andrew C ^b   De Hertogh, Gert ^c   Grin, Andrea ^a   Langer, Rupert ^d   Sagaert, Xavier ^c   Salemme, Marianna ^e   Streutker, Catherine J ^a   Soucy, Geneviève ^f   Tripathi, Monika ^g   Upton, Melissa P ^h   Vieth, Michael ⁱ   Villanacci, Vincenzo ^e  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY OF BERN   (Switzerland)

^e SPEDALI CIVILI   (Italy)

^f CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^g OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ INSTITUTE OF PATHOLOGY   (Germany)

Author keywords

Gastroesophageal junction; Her2; Immunohistochemistry; Intestinal metaplasia; Neoadjuvant; OESO; Pyloric gland adenoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADJUVANT THERAPY; ARTICLE; CARDIA; CLINICAL FEATURE; ENDOSCOPIC MUCOSAL RESECTION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL PYLORIC ADENOMA; ESOPHAGUS TUMOR; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LOWER ESOPHAGUS SPHINCTER; METAPLASIA; NONHUMAN; PANCREAS DISEASE; PANCREATIC METAPLASIA; STOMACH ADENOMA; TISSUE SECTION; TUMOR BIOPSY; TUMOR LOCALIZATION; ADENOCARCINOMA; ANIMAL; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; FRANCE; PATHOLOGY; PROCEDURES; STOMACH NEOPLASMS;

ADENOCARCINOMA; ANIMALS; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; ESOPHAGOSCOPY; HUMANS; PARIS; STOMACH NEOPLASMS;

EID: 84926081188     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12535     Document Type: Article

References (77)

1. Siewert, J.R., A.H. Holscher, K. Becker & W. Gossner . 1987. Kardiacarcinom: Versuch einer therapeutisch relevanten Klassifikation. Chirurg 58: 25-32.
2. Siewert, J.R. & H.J. Stein . 1998. Classification of adenocarcinoma of the oesophagogastric junction. Br. J. Surg. 85: 1457-1459.
3. Keeney, S. & T.L. Bauer . 2006. Epidemiology of adenocarcinoma of the esophagogastric junction. Surg. Oncol. Clin. N. Am. 15: 687-696.
4. Feith, M., H.J. Stein & J.R. Siewert . 2006. Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1602 consecutive resected patients. Surg. Oncol. Clin. N. Am. 15: 751-764.
5. Barbour, A.P., N.P. Rizk, M. Gonen, et al. 2007. Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann. Surg. 246: 1-8.
6. Dresner, S.M., P.J. Lamb, M.K. Bennett, et al. 2001. The pattern of metastatic lymph node dissemination from adenocarcinoma of the esophagogastric junction. Surgery 129: 103-109.
7. Marsman, W.A., G.N. Tytgat, F.J. ten Kate & J.J. van Lanschot . 2005. Differences and similarities of adenocarcinomas of the esophagus and esophagogastric junction. J. Surg. Oncol. 92: 160-168.
8. Rice, T.W., V.W. Rusch, C. Apperson-Hansen, et al. 2009. Worldwide Esophageal Cancer Collaboration. Dis. Esophagus 22: 1-8.
9. Gaur, P., W.L. Hofstetter, B.N. Bekele, et al. 2010. Comparison between established and the Worldwide Esophageal Cancer Collaboration Staging Systems. Ann. Thorac. Surg. 89: 1797-1804, e1793.
10. Rusch, V.W., T.W. Rice, J. Crowley, et al. 2010. The seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Staging Manuals: the new era of data-driven revisions. J. Thorac. Cardiovasc. Surg. 139: 819-821.
11. Wang, H.H., et al. 1986. Comparative features of esophageal and gastric adenocarcinomas: recent changes in type and frequency. Hum. Pathol. 17: 482-487.
12. McColl, K.E. & J.J. Going . 2010. Aetiology and classification of adenocarcinoma of the gastro-oesophageal junction/cardia. Gut 59: 282-284.
13. Derakhshan, M.H., et al. 2008. Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer. Gut 57: 298-305.
14. Demicco, E.G., et al. 2011. The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated adenocarcinoma. Mod. Pathol. 24: 1177-1190.
15. Huang, Q., et al. 2011. Comparison of gastro-oesophageal junction carcinomas in Chinese versus American patients. Histopathology 59: 188-197.
16. Srivastava, A., et al. 2007. Morphologic features are useful in distinguishing Barrett esophagus from carditis with intestinal metaplasia. Am. J. Surg. Pathol. 31: 1733-1741.
17. Hansen, S., et al. 2007. Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. Gut 56: 918-925.
18. Yantiss, R.K. 2010. Diagnostic challenges in the pathologic evaluation of Barrett esophagus. Arch. Pathol. Lab. Med. 134: 1589-600.
19. Odze, R.D. 2011. What the gastroenterologist needs to know about the histology of Barrett's esophagus. Curr. Opin. Gastroenterol. 27: 389-396.
20. Becker, K., R. Langer, D. Reim, et al. 2011. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann. Surg. 253: 934-939.
21. Chirieac, L.R., S.G. Swisher, J.A. Ajani, et al. 2005. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 103: 1347-1355.
22. Langer, R., K. Ott, M. Feith, et al. 2009. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Mod. Pathol. 22: 1555-1563.
23. Reim, D., R. Gertler, A. Novotny, et al. 2012. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer. Ann. Surg. Oncol. 19: 2108-2118.
24. Thies, S. & R. Langer . 2013. Tumor regression grading of gastrointestinal carcinomas after neoadjuvant treatment. Front Oncol. 3: 262.
25. Theisen, J., H.J. Stein & H.J. Dittler . 2002. Preoperative chemotherapy unmasks underlying Barrett's mucosa in patients with adenocarcinoma of the distal esophagus. Surg. Endosc. 16: 671-673.
26. Bosman, F.T., F. Carneiro, R.H. Hruban & N.D. Theise, Eds. 2010. WHO Classification of Tumours of the Digestive System. Lyon: World Health Organization.
27. Edge, S.B., D.R. Byrd, C.C. Compton, et al. 2009. AJCC Cancer Staging Manual. Berlin: Springer.
28. Sobin, L.H., M.K. Gospodarowicz & Ch. Wittekind, Eds . 2009. TNM Classification of Malignant Tumours, 7th Ed. New York: Wiley-Blackwell.
29. Kalish, R.J., P.E. Clancy, M.B. Orringer & H.D. Appelman . 1984. Clinical, epidemiologic, and morphologic comparison between adenocarcinomas arising in barretts esophageal mucosa and in the gastric cardia. Gastroenterology 86: 461-467.
30. Heidl, G., P. Langhans, W. Mellin, et al.1993. Adenocarcinomas of esophagus and cardia in comparison with gastric-carcinoma. J. Cancer Res. Clin. Oncol. 120: 95-99.
31. Sarbia, M. 2006. The histological appearance of oesophageal adenocarcinoma-an analysis based on 215 resection specimens. Virchows. Archiv. 448: 532-538.
32. Amano, Y., N. Ishimura, K. Furuta, et al. 2006. Which landmark results in a more consistent diagnosis of Barrett's esophagus, the gastric folds or the palisade vessels? Gastrointest. Endosc. 64: 206-211.
33. Senoo, M., F. Pinta & C.P. Crum . 2007. p63 is essential for the proliferative potential of stem cells in stratified epithelia. Cell 129: 523-569.
34. Wang, X., H. Ouyang, Y. Yamamoto, et al. 2011. Residual embryonic cells as precursors of Barrett's-like metaplasia. Cell 145: 1023-1035.
35. Patil, D.T., A. Bennett, D. Mahaja, et al. 2013. Distinguishing Barrett gastric foveolar dysplasia from reactive cardiac mucosa in gastroesophageal reflux disease. Hum. Pathol. 44: 1146-1153.
36. Xian, Y., K.Y. Ho, C.P. Crum . 2012. Cellular origin of Barrett's esophagus: controversy and therapeutic implications. Gastroenterology 142: 1424-1430.
37. Chandrasoma, P.T. et al. 2000. Histology of the gastroesophageal junction: an autopsy study. Am. J. Surg. Pathol. 24: 402-409.
38. Kilgore, S.P. et al. 2000. The gastric cardia: fact or fiction? Am. J. Gastroenterol. 95: 921-924.
39. Zhou, H. et al. 2001. Origin of cardiac mucosa: ontogenic consideration. Pediatr. Dev. Pathol. 4: 358-363.
40. Glickman, J.N. et al. 2002. Morphology of the cardia and significance of carditis in pediatric patients. Am. J. Surg. Pathol. 26: 1032-1039.
41. Chandrasoma, P.T. et al. 2000. Definition of histopathologic changes in gastroesophageal reflux disease. Am. J. Surg. Pathol. 24: 344-351.
42. Aida, J. et al. 2011. Palisade vessels as a new histologic marker of esophageal origin in ER specimens from columnar-lined esophagus. Am. J. Surg. Pathol. 35: 1140-1145.
43. Takubo, K. et al. 1991. Double muscularis mucosae in Barrett's esophagus. Hum. Pathol. 22: 1158-1161.
44. Lewis, J.T., K.K. Wang & S.C. Abraham . 2008. Muscularis mucosae duplication and the musculo-fibrous anomaly in endoscopic mucosal resections for barrett esophagus: implications for staging of adenocarcinoma. Am. J. Surg. Pathol. 32: 566-571.
45. Mandal, R.V. et al. 2009. Effect of tumor characteristics and duplication of the muscularis mucosae on the endoscopic staging of superficial Barrett esophagus-related neoplasia. Am. J. Surg. Pathol. 33: 620-625.
46. Takubo, K. et al. 2005. Islands of squamous epithelium and their surrounding mucosa in columnar-lined esophagus: a pathognomonic feature of Barrett's esophagus? Hum. Pathol. 36: 269-274.
47. Jovanovic, I. & Y.A. Mouzas . 2001. Gastric cardia cancer and precursor lesions- current dilemmas. Ann. Gastroenterol. 14: 244-251.
48. Kushima, R., M. Vieth, F. Borchard, et al. 2006. Gastric type well-differentiated adenocarcinoma and pyloric gland adenoma of the stomach. Gastric Cancer 9: 177-184.
49. Borchard, F., A. Ghanei, U. Koldovsky, et al. 1990. Gastrale Differenzierung in Adenomen der Magenschleimhaut. Immunohistochemische und elektronenmikroskopische Untersuchungen. Verh Dtsch. Ges. Pathol. 74: 528.
50. Vieth, M., C. Vogel, R. Kushima, et al. 2006. Pyloric gland adenoma: how to diagnose? Cesk. Patol. 42: 4-7.
51. Vieth, M., R. Kushima, F. Borchard, et al. 2003. Pyloric gland adenoma: a clinico-pathological analysis of 90 cases. Virchows. Arch. 442: 317-321.
52. Vieth, M., R. Kushima, J.P. de Jonge, et al. 2005. Adenoma with gastric differentiation (so-called pyloric gland adenoma) in a heterotopic gastric corpus mucosa in the rectum. Virchows. Arch. 446: 542-545.
53. Kushima, R., M. Vieth, K. Mukaisho, et al. 2005. Pyloric gland adenoma arising in Barrett's esophagus with mucin immunohistochemical and molecular cytogenetic evaluation. Virchows. Arch. 446: 537-541.
54. Buffart, T.E., B. Carvalho, T. Mons, et al. 2007. DNA copy number profiles of gastric cancer precursor lesions. BMC Genomics 8: 345.
55. Michal, M., R. Curik, K. Matler, et al. 2003. Regarding the paper by Vieth et al. Virchows Archiv. 442/4: 317-321. Virchows Arch. 443: 589-590.
56. Ahn, J.Y., S.O. Suh, J.O. Jung, et al. 2011. A case of pyloric gland adenoma in the cardia of the stomach, treated by endoscopic submucosal dissection. Korean J. Med. 80: 78-81.
57. Doglioni, C., L. Laurino, A.P. Dei Tos, et al. 1993. Pancreatic (acinar) metaplasia of the gastric mucosa. Histology, ultrastructure, immunocytochemistry, and clinicopathologic correlations of 101 cases. Am. J. Surg. Pathol. 17: 1134-1143.
58. Wang, H.H., J.M. Zeroogian, S.J. Spechler, et al. 1996. Prevalence and significance of pancreatic acinar metaplasia at the gastroesophageal junction. Am. J. Surg. Pathol. 20: 1507-1510.
59. Johansson, J., H.O. Hakansson, L. Mellblom, et al. 2005. Prevalence of precancerous and other metaplasia in the distal oesophagus and gastro-oesophageal junction. Scand. J. Gastroenterol. 40: 893-902.
60. Polkowski, W., J.J. van Lanschot, F.J. ten Kate, et al. 2000. Intestinal and pancreatic metaplasia at the esophagogastric junction in patients without Barrett's esophagus. Am. J. Gastroenterol. 95: 617-625.
61. Johansson, J., H.O. Hakansson, L. Mellblom, et al. 2010. Pancreatic acinar metaplasia in the distal oesophagus and the gastric cardia: prevalence, predictors and relation to GORD. J. Gastroenterol. 45: 291-299.
62. Luque-Barona, R.J., T. Pereda-Salguero & J. Fernandez-Alonso . 1999. So-called pancreatic acinar metaplasia of the gastric mucosa in two infants: a post-mortem study. Eur. J. Pediatr. 158: 267-268.
63. Huang, Q., J.S. Gold, J. Shi, et al. 2012. Pancreatic acinar-like adenocarcinoma of the proximal stomach invading the esophagus. Hum. Pathol. 43: 911-920.
64. Lee, H., L.H. Tang, E.F. Veras & D.S. Klimstra . 2012. The prevalence of pancreatic acinar differentiation in gastric adenocarcinoma: report of a case and immunohistochemical study of 111 additional cases. Am. J. Surg. Pathol. 36: 402-408.
65. Bang, Y.J. 2012. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer. J. Clin. Gastroenterol. 46: 637-648.
66. Bang, Y.J., E. Van Cutsem, A. Feyereislova, et al. 2010. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastroesophageal junction cancer (ToGA): a phase 3 open-label randomized controlled trial. Lancet 376: 687-697.
67. Rüschoff, J., W. Hanna, M. Bilous, et al. 2012. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 25: 637-650.
68. Begnami, M.D., E. Fukuda, J.H. Fregnani, et al. 2011. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J. Clin. Oncol. 29: 3030-3036.
69. Maresch, J., S.F. Schoppmann, C.M. Thallinger, et al. 2012. Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment. Crit. Rev. Oncol. Hematol. 82: 310-322.
70. Yoon, H.H., Q. Shi, W.R. Sukov, et al. 2012. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin. Cancer Res. 18: 546-554.
71. Phillips, B.E., R.R. Tubbs, T.W. Rice, et al. 2013. Clinicopathologic features and treatment outcomes of patient with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction. Dis. Esophagus 26: 299-304.
72. Odze, R.D. 2005. Unraveling the mystery of the gastroesophageal junction: a pathologist's perspective. Am. J. Gastroenterol. 100: 1853-1867.
73. Felley, C., H. Bouzourene, M.B. VanMelle, et al. 2012. Age, smoking and overweight contribute to the development of intestinal metaplasia of the cardia. World J. Gastroenterol. 18: 2076-2083.
74. Cestari, R., V. Villanacci, G. Bassotti, et al. 2007. The pathology of gastric cardia: a prospective, endoscopic, and morphologic study. Am. J. Surg. Pathol. 31: 706-710.
75. Goldblum, J.R. 2003. Barrett's esophagus and Barrett's-related dysplasia. Mod Pathol. 16: 316-324.
76. Cameron, A.J., E.O. Souto, T.C. Smyrk . 2002. Small adenocarcinomas of the esophagogastric junction: association with intestinal metaplasia and dysplasia. Am. J. Gastroenterol. 97: 1375-1380.
77. Cameron, A.J. 1994. Epidemiology of Barrett's esophagus. Gastroenterol. Clin. Biol. 18(1 Pt 2): D3-D4.